Category Archives: Regenerative Medicine

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ctijFXeY01M/gens-cellular-therapy-wave-finally.html

Stem Cell Meeting on the Mesa
The 2012 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the business development and scientific research communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by more than 600 leading scientists and researchers along side the regenerative medicine industry #39;s premier annual Investor and Partnering Forum designed to facilitate a bridge between academia and industry through one-on-one meetings and further the translation of clinical research. Scientific Meeting Agenda at a Glance 8:00 am -- Welcome Remarks Alan Trounson, President, California Institute for Regenerative Medicine 8:15 am -- Morning Keynote Speaker ** NO FILMING - Speaker did not consent to being recorded. Michele De Luca, Professor, Director, Centre for Regnerative Medicine, University of Modena and Reggio Emilia; Scientific Director, Holostem Terapie Avanzate Srl 8:45 am -- Panel 1: Cancer and Cancer Stem Cells Chair: Robert Wechsler-Reya, Professor, Director, Tumor Development Program, Sanford-Burnham Medical Research Institute Panelists: Jeremy Rich, Chairman, Department of Stem Cell Biology and Regenerative Medicine, The Cleveland Clinic Luke Lairson, Assistant Professor, The Scripps Research Institute Ben Spike, Senior Research Associate, Salk Institute for Biological Studies Catriona Jamieson, Associate Professor ...From:SalkInstituteViews:96 0ratingsTime:00:00More inScience Technology

Read more from the original source:
Stem Cell Meeting on the Mesa - Video

Stem cell commercialization panel discussion
How can companies make a business out of regenerative medicine, now that the science looks increasingly solid. Panel discussion Monday, Oct, 29 at Stem Cell Meeting on the Mesa tackles this. Speaking in this clip are are Dean Tozer of Shire Regenerative Medicine (pin-striped suit), Jay Siegel, Janssen Pharmaceutical Cops, (dark blue suit and tie), and Greg Lucier, Life Technologies, (lighter blue suit and tie), the moderator.From:Bradley FikesViews:139 0ratingsTime:06:43More inScience Technology

Continued here:
Stem cell commercialization panel discussion - Video

George Brown of Kool The Gang Talks About His Stem Cell Treatment At MetroMD Hollywood
Musician George Brown, an original member of the jazz funk band, Kool and The Gang, talks with us about his day at MetroMD. George was in Los Angeles on tour with rockers Van Halen David Lee Roth in June 2012. George had an orthopedic stem cell treatment performed by Dr. Alex Martin MD at about noon and was on stage performing 8 hours later. For more info, visit us at MetroMD.net or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:21 0ratingsTime:02:02More inScience Technology

Read more:
George Brown of Kool

Sunday, Nov. 4, 2012

A science ministry working group studying stem cells and regenerative medicine has updated its road map on induced pluripotent stem-cell research, aiming to create human organs including brains, lungs and kidneys via iPS cells within 10 years.

The group's updated plan, first compiled in 2009, calls for the distribution of iPS cells for regenerative medicine to start within the next two to three years. The announcement comes after Kyoto University professor Shinya Yamanaka jointly won this year's Nobel Prize in physiology or medicine for his revolutionary work in developing iPS cells.

The new road map includes a plan by the government-backed Riken research institute to begin a clinical study in fiscal 2013 on the transplantation of retinas created through iPS cells into patients suffering age-related deterioration in their vision.

In addition, a clinical study on heart muscle will start within three to five years, targeting patients who have suffered heart attacks or are experiencing other cardiac diseases. A study on brain nerve cells will also be launched in five to seven years, mainly for patients afflicted with Parkinson's disease.

Riken official Shinichi Nishikawa, also a member of the ministry's working group, said researchers from various fields should cooperate in compiling safety standards on the use of iPS cells.

The science ministry has sought 8.7 billion for research related to regenerative medicine as part of its budget request for fiscal 2013.

Continue reading here:
New iPS goal: brains, lungs, kidneys

TORONTO, ONTARIO--(Marketwire - Oct 29, 2012) - The collaborative network created by the Centre for Commercialization of Regenerative Medicine (CCRM) has been strengthened with the addition of Stem Cell Therapeutics Corp. to its 20-member industry consortium.

"I am pleased to welcome Stem Cell Therapeutics Corp. to the industry consortium," says Dr. Michael May, CEO of CCRM. "Since our Centre mobilizes business and scientific expertise to translate regenerative medicine (RM) and stem cell-based medical discoveries into commercial products and therapies, the industry consortium provides critical expertise, experience and market-pull information for the development of innovative RM technologies. We are delighted to have them on board."

CCRM is working with its industry consortium to address real-life bottlenecks in their RM and stem cell-based product pipelines. The companies in the industry consortium represent the key sectors of the industry: therapeutics, devices, reagents, and cells as tools.

"Being included in CCRM''s industry consortium is a step in the repositioning of our company - an aim described in our corporate objectives - to participate along with the other 20 Canadian, American and international companies," says David Allan, Executive Chairman of Stem Cell Therapeutics Corp. "The concept of CCRM as a hub for the commercialization of Canada''s extraordinary commitment to stem cell research, and its provision of facilities and infrastructure, is outstanding.

"As Canada''s only public company dedicated to the development of stem cell therapeutics from academic research, we hope to become one of CCRM''s commercialization partners of choice for the novel work ongoing at so many of Canada''s internationally recognized academic centres."

To-date, CCRM has launched its first industry project with EMD Millipore and created an innovation fund with Pfizer Canada. CCRM has built three core development platforms: reprogramming and engineering; cell manufacturing; and, biomaterials and devices to carry out projects commissioned by academia and industry. CCRM has a fully resourced, 6,000 square foot development facility where all development work takes place.

Please visit http://www.ccrm.ca to see a complete list of CCRM''s industry consortium members.

About the Centre for Commercialization of Regenerative Medicine (CCRM)

CCRM, a Canadian not-for-profit organization funded by the Government of Canada''s Networks of Centres of Excellence program and six academic partners, supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. A network of academics, industry and entrepreneurs, CCRM aims to translate scientific discoveries into marketable products for patients. CCRM launched in Toronto''s Discovery District on June 14, 2011.

Read more:
Canadian Regenerative Medicine Community Growing Stronger

Update in Preventative / Regenerative Medicine - by Ron Rothenberg, MD
Update in Preventative/Regenerative Medicine -- Inflammation, Hormones, Stem Cells and Telomeres- by Ron Rothenberg, MD on August 2012 Visit the Silicon Valley Health Institute (aka Smart Life Forum) at http://www.svhi.comFrom:Mike KorekViews:9 0ratingsTime:01:40:35More inScience Technology

Continued here:
Update in Preventative / Regenerative Medicine - by Ron Rothenberg, MD - Video

George Brown of Kool The Gang Talks About His Stem Cell Treatment At MetroMD Hollywood
Musician George Brown, an original member of the jazz funk band, Kool and The Gang, talks with us about his day at MetroMD. George was in Los Angeles on tour with rockers Van Halen David Lee Roth in June 2012. George had an orthopedic stem cell treatment performed by Dr. Alex Martin MD at about noon and was on stage performing 8 hours later. For more info, visit us at MetroMD.net or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:6 0ratingsTime:02:02More inScience Technology

Read the original:
George Brown of Kool

NEW YORK, Nov. 1, 2012 (GLOBE NEWSWIRE) -- The Stem for Life Foundation, NeoStem, Inc. (NYSE MKT:NBS), The Pontifical Council for Culture, and STOQ International today announced that they will host The Second International Vatican Adult Stem Cell Conference: Regenerative Medicine -- A Fundamental Shift in Science & Culture, from within The Vatican, April 11-13, 2013.

This event is part of a five-year collaboration between The Stem for Life Foundation, a not-for-profit organization devoted to raising global awareness of the therapeutic potential of adult stem cells, NeoStem, an emerging leader in the fast growing cell therapy industry, The Vatican's Pontifical Council for Culture and its foundation, called STOQ International (Science, Theology and the Ontological Quest).

With renowned journalists serving as moderators -- Meredith Vieira from NBC News, Bill Hemmer from The Fox News Channel, Peggy Noonan of The Wall Street Journal and Dr. Max Gomez from WCBS-TV -- The Second International Vatican Adult Stem Cell Conference will feature leading adult stem cell scientists and clinicians, thought leaders of faith, ethics and culture, business leaders as well as Ministers of Health, Ambassadors to The Holy See and regulatory officials from around the world. During the event, adult stem cell scientists and clinicians will present an array of medical advancements and ongoing research occurring throughout the world, including the ability to grow replacements for damaged and diseased organs; restoring heart function after heart attack; growing new skin for burn victims; rebalancing our own immune systems, pushing back a rising tide of chronic disease; advancements in cancer therapy; preventing organ rejection and addressing a range of other conditions and trauma, such as MS, traumatic brain injuries and cardiovascular disease via adult stem cell therapies. Throughout the event, patients will share their own stories of the unique, powerful treatments that have helped address their disease and reduce suffering.

"Regenerative medicine is poised to revolutionize disease management by finding new ways to boost the body's ability to heal itself. Whereas today treatment for many diseases is a matter of managing symptoms, regenerative medicine seeks to reverse the course of the disease by targeting its cause and repairing diseased or defective tissues or organs," said Dr. Robin Smith, President of The Stem for Life Foundation. "Not only will our conference educate people of all ages, religions and cultures on the potential of adult stem cells to treat chronic disease as part of this next great frontier, but we will generate a truly international dialogue on regenerative medicine, one that explores the interconnections between scientific breakthroughs, faith, culture and ethics."

The goals of the 2013 Second International Vatican Adult Stem Cell Conference are to:

"The developments within regenerative medicine are of great interest," said Msgr. Tomasz Trafny. "They show how science changes, causing paradigm shifts through interdisciplinary research. Cellular biology is a good example of such changes. These dynamics also cause deep cultural transformations on different levels, from health care to economy, from new technologies to legal issues. Thus, topics that apparently seem to be circumscribed only to strictly scientific discussions or theoretical ones, in fact modify our understanding of social dynamics, relationships and, in the ultimate analysis, our understanding of the human being. Today we acknowledge that insights from natural sciences play a crucial role in our society, having consequences for anthropology, philosophy and even theology. It is our mission and our duty to explore the above dynamics, to offer the best tools for pastoral care, and to encourage understanding of changing culture."

In June, The Pontifical Council for Culture and The Stem for Life Foundation presented the first copy of their forthcoming book, The Healing Cell: How The Greatest Revolution in Medical History is Changing Your Life, to The Holy Father, Pope Benedict XVI. The book is the result of a unique collaboration between the two organizations, and will be available in 2013. It includes a special address by His Holiness Benedict XVI, urging increased support and awareness for advancements in adult stem cell research in order to alleviate human suffering. To reserve a copy of the book, go to:http://www.stemforlife.org/healingcell

To learn more about The Second International Vatican Adult Stem Cell Conference please visit http://www.adultstemcellconference.org.

About The Pontifical Council for Culture

The Pontifical Council for Culture is that Dicastery of the Roman Curia which assists the Pope in the exercise of his supreme pastoral office for the benefit and service of the universal Church and of particular Churches concerning the encounter between the saving message of the Gospel and cultures, in the study of the weighty phenomena of the rift between the Gospel and cultures; indifference in matters of religion; unbelief. It is also concerned with relationships between the Church and the Holy See and the world of culture; in particular it promotes dialogue with contemporary cultures, so that human civilization may become increasingly open to the Gospel, and so that men and women of science, letters and the arts may know that the Church acknowledges their work as a service to truth, goodness and beauty. http://www.cultura.va

Read the rest here:
The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Announce 'The ...

San Diego, CA/PRNewswire/ - ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that it has received a$10.1 millionStrategic Partnership Award from the California Institute for Regenerative Medicine (CIRM).

ViaCyte's innovative stem cell-based therapy for diabetes has been supported by several previous rounds of funding from CIRM, including a$20 millionDisease Team Award in 2009. This support has directly aided the development of VC-01, a regenerative medicine, combination product consisting of pancreatic beta cell progenitors encapsulated in a durable macroencapsulation device. When implanted under the skin of a patient with diabetes, VC-01 is expected to produce insulin and other factors which should safely and effectively control their disease. In its review of ViaCyte's application, CIRM's Grants Working Group characterized the Company's proposed therapy as the "holy grail" of diabetes treatments.

ViaCyte recently held a successful Pre-IND meeting with the United States Food and Drug Administration (FDA) and is on track to file an Investigational New Drug (IND) Application and initiate clinical evaluation of VC-01 in 2014. The Strategic Partnership Award from CIRM will be used to support these efforts, reflecting CIRM's commitment to following promising science through the progressive stages of product development.

"We are very grateful for the assistance that we are receiving from CIRM to advance our promising technology", stated Dr.Paul Laikind, President and CEO of ViaCyte. "Today's grant allows us to continue our efforts on behalf of theCaliforniataxpayers to break new ground with our stem cell-based product that has the potential to essentially cure patients with type 1 diabetes and provide a powerful new treatment for those with type 2 disease as well."

Approval of the award came from CIRM's governing board, the Independent Citizens Oversight Committee (ICOC), with advisement from the Scientific and Medical Research Funding Working Group. "ViaCyte has made good on their initial Disease Team award from CIRM, including a successful Pre-IND FDA meeting, and as a consequence, CIRM and the ICOC are glad to have the opportunity to continue funding ViaCyte's efforts to provide this product to patients with diabetes inCaliforniaand the rest of the world," said Dr.Alan Trounson, President of CIRM.

About ViaCyte

ViaCyte is a private company focused on developing a novel cell therapy for the treatment of diabetes. The Company's technology is based on the production of pancreatic beta cell progenitors derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.

ViaCyte is headquartered inSan Diego, Californiawith additional operations inAthens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.

This news release may contain forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995.

About CIRM

Read the original:
ViaCyte Receives $10.1M Strategic Partnership Award From CIRM To Continue Development Of Diabetes Therapy